Physician profile
Bimu Risal Risal Bhandary
NPI 1821686718
$3,803.01
in general payments reported to CMS, 2019-2025
25 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $1,456 · 2024: $1,019 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $651.75 | 2023-2025 | Watchman Access System, Watchman Flx, Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $643.94 | 2023-2025 | Farxiga, Tezspire, Lokelma |
| Novo Nordisk INC | $617.20 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $296.30 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $265.31 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $265.27 | 2023-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.92 | 2022-2025 | Jardiance |
| Pfizer INC. | $133.39 | 2024-2025 | |
| Gilead Sciences, INC. | $121.84 | 2025 | Yeztugo |
| Lilly USA, LLC | $113.63 | 2024-2025 | Mounjaro, Zepbound |
| Irhythm Technologies, INC. | $102.55 | 2024 | Zio Monitor, Zio Xt Patch |
| E.R. Squibb & Sons, L.L.C. | $63.47 | 2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $49.48 | 2024 | Inpefa |
| Bridgebio Pharma, INC. | $46.37 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.74 | 2024-2025 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $30.21 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $20.60 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $19.27 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $18.91 | 2023 | Injectafer |
| Philips North America LLC | $18.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.76 | 2025 | |
| Heartflow, INC. | $17.23 | 2025 | |
| Esperion Therapeutics, INC. | $16.58 | 2024 | Nexletol |
| Tactile Systems Technology INC | $15.35 | 2024 | Flexitouch Plus, Entre Plus |
| Scpharmaceuticals INC. | $13.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimu Risal Bhandary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.